Ginkgo Bioworks Holdings, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $19.5M | $54.0M | $38.8M | $39.1M | $38.2M | $43.8M | $89.0M |
| Cost of Revenue | $1.7M | $3.1M | — | — | $5.4M | $4.1M | — | — |
| Gross Profit | $18.4M | $16.4M | — | — | $33.8M | $34.1M | — | — |
| Gross Margin | 91.5% | 84.1% | — | — | 86.3% | 89.3% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $46.2M | $49.9M | $50.1M | $69.4M | $53.4M | $70.9M | $76.4M | $77.0M |
| SG&A Expense | $30.8M | $37.8M | $63.6M | $45.0M | $35.0M | $39.7M | $57.3M | $52.3M |
| Operating Income | $-58.5M | $-71.4M | $-86.1M | $-90.0M | $-58.2M | $-81.0M | $-103.6M | $-55.2M |
| Operating Margin | -290.5% | -366.5% | -159.6% | -231.8% | -148.6% | -211.8% | -236.3% | -62.0% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-57.2M | $-76.1M | $-96.1M | $-80.8M | $-53.5M | $-83.2M | $-107.9M | $-56.8M |
| Income Tax Expense | $128.0K | $-80.0K | $-643.0K | $1.0K | $-283.0K | $88.0K | $-325.0K | $-375.0K |
| Net Income | $-46.7M | $-82.6M | $-80.8M | $-80.8M | $-60.3M | $-91.0M | $-107.5M | $-56.4M |
| Net Margin | -231.7% | -424.1% | -149.7% | -207.9% | -154.1% | -237.9% | -245.2% | -63.3% |
| EPS (Basic) | $-0.75 | $-1.39 | $-1.41 | $-1.45 | $-1.10 | $-1.68 | $-1.92 | $-1.08 |
| EPS (Diluted) | — | — | $-1.41 | $-1.45 | $-1.10 | $-1.68 | $-1.91 | $-1.08 |
| Shares Outstanding (Basic) | 62.1M | 59.6M | 55.5M | 55.6M | 54.9M | 54.2M | 51.9M | 52.2M |
| Shares Outstanding (Diluted) | 62.1M | 59.6M | 55.5M | 55.6M | 54.9M | 54.2M | 51.9M | 52.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |